0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Innovation1 Biotech
Its shares trade under the ticker IVBT. It has been listed since 6 February 2017. In the fiscal year to 31 August 2021, it reported revenue of $3,080 and net income of $1.0m. At that date it held total assets of $181,886 and shareholders' equity of −$224,839.
Innovation1 Biotech, Inc. is a drug discovery company, which engages in the development of modified Schedule 1 molecules of botanical origin to create derivatives for treatment of neurologic, psychiatric, dermatologic, and ophthalmologic disorders. The company is headquartered in Rockaway, New Jersey. The company went IPO on 2017-02-06. The company has a portfolio of products using five preclinical prodrugs, all fully synthetic without connection to botanical sourcing: a mushroom-derived psychedelic molecule for treatment of post-traumatic stress disorder and depression, a cannabinoid and tree bark derived psychedelic for treatment of addiction and three additional cannabinoid prodrugs addressing clinical indications of refractory pediatric epilepsy, hypertrophic scarring, and ocular inflammation. The first agent is a prodrug of psilocin, a molecule naturally found in certain mushroom species. The second agent is a prodrug of synthetic tetrahydrocannobivarin, a molecule naturally found in Cannabis that modulates the two principal cannabinoid receptors: CBR1 and CBR2. The third agent is a prodrug of synthetic cannabidophorol.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 6 Feb 2017
Leadership
Pay as last reported
- Mr. Frederick PierceChairman of the Board, President, Interim Acting Chief Executive Officer, since 2022
- Mr. Samuel KnipperChief Financial Officer
- Mr. Charles AllenTreasurer, Company Secretary, Independent Director, since 2022
- Dr. Shahin GharakhanianIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovation1 Biotech Inc develops modified Schedule 1 molecules for neurologic and psychiatric disorders treatment.
- The company has five preclinical prodrugs fully synthetic without botanical sourcing.
- Innovation1 Biotech Inc's portfolio includes a mushroom-derived psychedelic for PTSD and depression treatment.
Weaknesses
- The company's first agent is a prodrug of psilocin from mushrooms.
- Innovation1 Biotech Inc's second agent uses synthetic tetrahydrocannobivarin from Cannabis.
- The company's third agent is a prodrug of synthetic cannabidophorol for pediatric epilepsy.
Opportunities
- Innovation1 Biotech Inc's portfolio addresses refractory pediatric epilepsy with cannabinoid prodrugs.
- The company has potential for treating addiction using tree bark derived psychedelic agents.
- Innovation1 Biotech Inc's prodrugs target ocular inflammation and hypertrophic scarring.
Threats
- The company's Schedule 1 molecule development faces regulatory challenges in the US.
- Innovation1 Biotech Inc's botanical origin derivatives may encounter legal restrictions.
- The company's focus on psychedelic treatments could face public perception issues.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.